David Nalin

Q: What Schools Are Affiliated With David Nalin

David Nalin is affiliated with the following schools: University of Texas Medical Branch, Albany Medical College, University System of Maryland, Cornell University

David Nalin's AcademicInfluence.com Rankings

David Nalin

Biology

#5539

World Rank

#8045

Historical Rank

#1896

USA Rank

Physiology

#350

World Rank

#565

Historical Rank

#50

USA Rank

biology Degrees

Download Badge

Biology

Why Is David Nalin Influential?

(Suggest an Edit or Addition)

According to Wikipedia, David R. Nalin is an American physiologist, and Pollin Prize for Pediatric Research and Prince Mahidol Award, a.k.a. Mahidol Medal winner. Nalin had the key insight that oral rehydration therapy would work if the volume of solution patients drank matched the volume of their fluid losses, and that this would drastically reduce or completely replace the only current treatment for cholera, intravenous therapy. Nalin led the trials that first demonstrated ORT works, both in cholera patients, and more significantly, also in other dehydrating diarrhea illnesses. Nalin's discoveries have been estimated to have saved over 50 million lives worldwide.

(See a Problem?)

David Nalin's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

ESCHERICHIA COLI STRAINS THAT CAUSE DIARRHŒA BUT DO NOT PRODUCE HEAT-LABILE OR HEAT-STABLE ENTEROTOXINS AND ARE NON-INVASIVE (1978) (687)
Duration of infection-derived immunity to cholera. (1981) (253)
Oral maintenance therapy for cholera in adults. (1968) (241)
Immunity of cholera in man: relative role of antibacterial versus antitoxic immunity. (1979) (185)
Immunity to Enterotoxigenic Escherichia coli (1979) (178)
Adsorption and growth of Vibrio cholerae on chitin (1979) (169)
Ivermectin for human strongyloidiasis and other intestinal helminths. (1989) (158)
Fever as an adverse event following immunization: case definition and guidelines of data collection, analysis, and presentation. (2004) (147)
Adverse Events Associated with Childhood Vaccines: Evidence Bearing on Causality (1994) (143)
Effect of glycine and glucose on sodium and water absorption in patients with cholera (1970) (141)
Control of hepatitis A through routine vaccination of children. (2001) (126)
Evaluation of influenza A/Hong Kong/123/77 (H1N1) ts-1A2 and cold-adapted recombinant viruses in seronegative adult volunteers. (1980) (96)
CHOLERA, NON-VIBRIO CHOLERA, AND STOMACH ACID (1978) (95)
Duration of protection from clinical hepatitis A disease after vaccination with VAQTA® (1996) (94)
A clinical trial of oral therapy in a rural cholera-treatment center. (1970) (94)
FAILURE OF SANITARY WELLS TO PROTECT AGAINST CHOLERA AND OTHER DIARRHŒAS IN BANGLADESH (1976) (94)
Oral rehydration and maintenance of children with rotavirus and bacterial diarrhoeas. (1979) (94)
The pathogenicity of nonenterotoxigenic Vibrio cholerae serogroup O1 biotype El Tor isolated from sewage water in Brazil. (1982) (93)
Safety and immunogenicity of a live attenuated hepatitis A virus vaccine in seronegative volunteers. (1991) (90)
Antibody persistence after primary measles-mumps-rubella vaccine and response to a second dose given at four to six vs. eleven to thirteen years. (1996) (85)
COMPARISON OF SUCROSE WITH GLUCOSE IN ORAL THERAPY OF INFANT DIARRHŒA (1978) (84)
Worldwide experience with the CR326F-derived inactivated hepatitis A virus vaccine in pediatric and adult populations: an overview. (1993) (82)
Genetic susceptibility to cholera. (1979) (82)
The effect of age and weight on the response to formalin inactivated, alum-adjuvanted hepatitis A vaccine in healthy adults. (1997) (79)
Fever after immunization: current concepts and improved future scientific understanding. (2004) (69)
Use of norfloxacin to treat chronic typhoid carriers. (1988) (68)
ORAL THERAPY WITH GLUCOSE ELECTROLYTE SOLUTION (1980) (66)
Comparison of low and high sodium and potassium content in oral rehydration solutions. (1980) (61)
Six years' follow-up after hepatitis A vaccination. (1998) (57)
Oral (or nasogastric) maintenance therapy for cholera patients in all age-groups. (1970) (55)
Measles vaccine immunogenicity in 6- versus 15-month-old infants born to mothers in the measles vaccine era. (1994) (55)
CHOLERA, COPEPODS, AND CHITINASE (1976) (52)
CANNABIS, HYPOCHLORHYDRIA, AND CHOLERA (1978) (52)
Immune response to measles vaccine in 6-month-old infants of measles seronegative mothers. (1998) (51)
Immunoprecipitation and virus neutralization assays demonstrate qualitative differences between protective antibody responses to inactivated hepatitis A vaccine and passive immunization with immune globulin. (1997) (49)
ORAL REHYDRATION OF NEONATES WITH DEHYDRATING DIARRHŒAS (1979) (49)
Sensitive assays for hepatitis a antibodies (1993) (49)
Lack of person-to-person transmission of enterotoxigenic Escherichia coli despite close contact. (1980) (48)
Oral or nasogastric maintenance therapy in pediatric cholera patients. (1971) (48)
Oral or nasogastric maintenance therapy for diarrhoea of unknown aetiology resembling cholera. (1970) (43)
ENTEROTOXIGENIC ESCHERICHIA COLI AND IDIOPATHIC DIARRHŒA IN BANGLADESH (1975) (43)
Guidelines for collection, analysis and presentation of vaccine safety data in pre- and post-licensure clinical studies. (2009) (43)
Effectiveness of hepatitis A vaccine in a former frequently affected community: 9 years' followup after the Monroe field trial of VAQTA. (2002) (41)
Immunogenicity of two versus three injections of inactivated hepatitis A vaccine in adults. (1997) (41)
Survival of a patient with intestinal anthrax. (1977) (39)
CHLOPROMAZINE AND CHOLERA (1979) (39)
Guidelines for collection, analysis and presentation of vaccine safety data in surveillance systems. (2009) (37)
SUCROSE IN ORAL THERAPY FOR CHOLERA AND RELATED DIARRHŒAS (1975) (36)
Rapid correction of acidosis and dehydration of cholera with oral electrolyte and glucose solution. (1970) (35)
Concurrent administration of inactivated hepatitis A vaccine with immune globulin in healthy adults. (1999) (33)
The problem of emesis during oral glucose-electrolytes therapy given from the onset of severe cholera. (1979) (31)
Acetate in the correction of acidosis secondary to diarrhoea. (1969) (31)
Evaluation of oral therapy for infant diarrhoea in an emergency room setting: the acute episode as an opportunity for instructing mothers in home treatment. (1979) (31)
Cholera-like toxic effect of culture filtrates of Escherichia coli. (1974) (29)
Safety, tolerability, and immunogenicity of an inactivated hepatitis A vaccine: effects of single and booster injections, and comparison to administration of immune globulin. (1993) (28)
50 years of oral rehydration therapy: the solution is still simple (2018) (27)
Safety profile and immunogenicity of an inactivated vaccine derived from an attenuated strain of hepatitis A. (1992) (27)
Treatment of diarrhea. (1977) (25)
Comparative susceptibilities of Campylobacter pylori to norfloxacin and other agents (1987) (24)
Evaluating mumps vaccines (1992) (24)
MUMPS VACCINE COMPLICATIONS: WHICH STRAIN? (1989) (24)
Effect of cholera toxin on jejunal osmoregulation of mannitol solutions in dogs. (1972) (23)
Enterotoxigenic Escherichia coli and idiopathic diarrhoea in Bangladesh. (1975) (22)
Safety and immunogenicity of early measles vaccination in children born to HIV-infected mothers in the United States: results of Pediatric AIDS Clinical Trials Group (PACTG) protocol 225. (2011) (20)
Saliva and serum as diagnostic media for antibody to hepatitis A virus in adults and in individuals who have received an inactivated hepatitis A vaccine. (1995) (20)
Template protocol for clinical trials investigating vaccines--focus on safety elements. (2013) (19)
Clinical concerns about reduced-osmolarity oral rehydration solution. (2004) (18)
Immunogenicity, safety and tolerability of varying doses and regimens of inactivated hepatitis A virus vaccine in Navajo children. (1994) (18)
A simple antigen-reduction assay for the measurement of neutralizing antibodies to hepatitis A virus. (1991) (17)
Epidemic of suicide by malathion poisoning in Guyana. Report of 264 cases. (1973) (17)
Inactivated hepatitis A vaccine in childhood: implications for disease control. (1993) (16)
A point survey of periurban and urban malaria in Karachi. (1985) (16)
Evidence based vaccinology. (2002) (16)
Increased Escherichia coli enterotoxin detection after concentrating culture supernatants: possible new enterotoxin detectable in dogs but not in infant mice (1978) (15)
Effects of choleragenoid and glucose on the response of dog intestine to escherichia coli enterotoxins. (1978) (14)
SODIUM CONTENT IN ORAL THERAPY FOR DIARRHŒA (1976) (14)
VITAMIN A, XEROPHTHALMIA, AND DIARRHŒA (1980) (12)
ORAL SUCROSE THERAPY FOR DIARRHŒA (1975) (12)
Mumps, measles, and rubella vaccination and encephalitis. (1989) (12)
Cholera Toxoid Boosts Serum Escherichia coli Antitoxin in Humans (1974) (11)
Hepatitis infections in the day-care setting. (1994) (11)
Colonization of Ascaris lumbricoides by V. cholerae. (1976) (11)
Formulation of oral rehydration solution (2002) (10)
CHOLERA TRANSMISSION NEAR A CHOLERA HOSPITAL (1976) (10)
CHOLERA IS PRIMARILY WATERBORNE IN BANGLADESH (1976) (9)
Oral Therapy for Cholera (1970) (8)
Monthly Update: Anti-infectives: VAQTA: Merck's hepatitis A vaccine, purified, inactivated (1995) (8)
Cholera and severe toxigenic diarrhoeas. (1994) (8)
Solid-Phase Microtiter Radioimmunoassay Blocking Test for Detection of Antibodies to Escherichia coli Heat-Labile Enterotoxin (1979) (8)
Measles vaccine immunogenicity and antibody persistence in 12 vs 15-month old infants. (2000) (8)
DEATH OF CHILD SUBMITTED TO UVULECTOMY FOR DIARRHOEA (1985) (7)
Effect on clinical outcome of breast feeding during acute diarrhoea. (1985) (6)
Recognition and treatment of anthrax. (1999) (6)
Low incidence of adverse experiences after measles or measles-rubella mass revaccination at a college campus. (1994) (6)
A dose response study of hepatitis A vaccine in healthy adults who are > or = 30 years old and weigh > or = 77 kg. (1998) (6)
Oral therapy for diarrhoea. (1977) (5)
Comment on: unexpected antimicrobial effect of statins. (2008) (5)
Oral or nasogastric therapy for cholera. (1970) (5)
Fecal steroids in diarrhea. III. Experimentally-induced travellers' diarrhea. (1980) (5)
Diarrhoea resembling cholera induced by Escherichia coli culture filtrate. (1973) (5)
Temperature-sensitive mutants of influenza A virus: Evaluation of the Alaska/77-ts-1 A 2 temperature-sensitive recombinant virus in seronegative adult volunteers (2005) (5)
Oral rehydration for cholera. (2009) (5)
A SPOONFUL OF SUGAR ... (1978) (5)
Fecal steroids in diarrhea: IV. Cholera (1982) (4)
Re: V. Usonis et al.: Comparative study of reactogenicity and immunogenicity of new and established measles, mumps and rubella vaccines in healthy children (infection 26 [1998] 222–226) (1999) (4)
FAILURE OF ASPIRIN TO REVERSE INTESTINAL SECRETION AFTER CHOLERA TOXIN IN DOGS (1976) (4)
Live Victoria/75-ts-1[E] Influenza A Virus Vaccines in Adult Volunteers: Role of Hemagglutinin Immunity in Protection Against Illness and Infection Caused by Influenza A Virus (1979) (4)
Immunosenescence and SARS-CoV-2 Vaccine Development (2020) (4)
CHOLERA RESEARCH IN BANGLADESH (1978) (3)
Formulation of oral rehydration solution [letter] (2002) (3)
Mortality from cholera and other diarrhoeal diseases at a cholera hospital. (1972) (3)
CHOLERA RESEARCH IN BANGLADESH (1978) (3)
Part three: Folk beliefs about cholera among Bengali Muslims and Mogh Buddhists in Chittagong, Bangladesh (1977) (3)
Ebola and Cholera (2015) (3)
Imipenem/cilastatin for pediatric infections in hospitalized patients. (1987) (3)
Oral therapy for dehydration in acute diarrhoeal diseases with special reference to the global Diarrhoeal Diseases Control Programme. (1979) (3)
CHOICE Study Group Trial. (2002) (3)
Cholera and Pancreatic Cholera: Is VIP the Common Pathophysiologic Factor? (2020) (3)
Gram Staining by Physicians: An Invaluable Practice Still Seen in East Asia (2010) (3)
Ex vivo antigen-pulsed PBMCs generate potent and long lasting immunity to infection when administered as a vaccine. (2017) (3)
Diarrhea resembling cholera induced by Escherichia coli culture filtrate. (1973) (3)
Issues and Controversies in the Evolution of Oral Rehydration Therapy (ORT) (2021) (3)
ASPIRIN AND FLUID LOSSES IN DIARRHŒA (1980) (3)
Imipenem/cilastatin therapy for serious infections in neonates and infants. (1987) (2)
BLOOD GROUP SUBSTANCES IN PNEUMOCOCCAL VACCINE (1988) (2)
Comparison of oral rehydration solutions. (1989) (2)
Renal function in acute Asiatic cholera. (1973) (2)
Biohydrogenation of cholesterol as an index of bacterial 7α-dehydroxylase activity (1981) (2)
Oral rehydration and hyponatraemia (1999) (2)
Zinc and cholera. (2005) (2)
Hepatitis A Vaccines-Reply (1996) (2)
Comparison of efficacy of oral rehydration fluids administered at 37 degrees C or 23 degrees C. (1987) (2)
Oral therapy for cholera: amino acids added to electrolyte solutions containing rice or glucose. (2006) (1)
[Rehydration by the oral route and its maintenance in patients from birth to 3 months old dehydrated due to diarrhea]. (1980) (1)
Oral therapy for diarrheal diseases. (1987) (1)
ENTEROTOXIGENIC E. COLI IN BANGLADESH (1976) (1)
Oral replacement of water and electrolyte losses due to travellers' diarrhoea. (1983) (1)
CHOLERA PATHOPHYSIOLOGY: HAVE WE MISSED THE BOAT? (2021) (1)
ORAL THERAPY FOR DIARRHŒA (1977) (1)
SUCROSE OR GLUCOSE FOR DIARRHŒA (1977) (1)
Recent advances in cholera pathophysiology and therapeutics. (1975) (1)
Rapid formation of specific neutralizing antibodies to HAV following a single dose of an inactivated hepatitis A virus vaccine (1990) (1)
INTRALUMINAL BINDING OF CHOLERA TOXIN (1981) (1)
VILLAGE HEALTH EDUCATION AND ORAL DIARRHŒA THERAPY (1980) (1)
Letter: Oral sucrose therapy for diarrhoea. (1975) (0)
Solutions for oral rehydration [letter] (1987) (0)
Cholera or choleric? (2008) (0)
Antihelminthic Efficacy Against Trichuriasis. (2019) (0)
Points: Diarrhoea, dehydration, and drugs (1985) (0)
Oral rehydration therapy (2009) (0)
CHOICE Study Group Trial (2002) (0)
Comparing immunogenicity of two measles, mumps and rubella vaccines. (1999) (0)
Oral rehydration therapy history: a correction (2018) (0)
Chlorpromazine and cholera. (1979) (0)
The cover art of the 15 June 2004 issue. (2004) (0)
The History of Intravenous and Oral Rehydration and Maintenance Therapy of Cholera and Non-Cholera Dehydrating Diarrheas: A Deconstruction of Translational Medicine: From Bench to Bedside? (2022) (0)
The gastric barrier to intestinal infection (1979) (0)
Zinc and cholera. Authors' reply (2005) (0)
Oral therapy with glucose electrolyte solution. [Letter] (1980) (0)
Escherichia Coli Culture Filtrate Includes Diarrhea Resembling Cholera (2003) (0)
Cholera control requires reducing mortality along with vaccination programs. (2022) (0)
Failure of oral glucose therapy in short-bowel syndrome. (1972) (0)
COMMENT ON : COMPARATIVE STUDY OF REACTOGENICITY AND IMMUNOGENICITY OF NEWAND ESTABLISHED MEASLES, MUMPS AND RUBELLA VACCINES IN HEALTHY CHILDREN. AU THOR'S CONCLUDING STATEMENT (1999) (0)
Blood group A substances are not present in currently available pneumococcal vaccine. (1988) (0)
O come, let us wallow in glorious mud. (1996) (0)
Zinc and Cholera Reply to Nalin (0)
RECOGNITION AND TREATMENT OF ANTHRAX. AUTHORS' REPLY (1999) (0)
Comparison of low and high sodium content in oral rehydration solutions and potassium (1980) (0)
TESTING FOR CHOLERA ANTAGONISTS (1977) (0)
Correction: Nalin, D. Issues and Controversies in the Evolution of Oral Rehydration Therapy (ORT). Trop. Med. Infect. Dis. 2021, 6, 34 (2022) (0)
Cholera toxide boots serum coli antitoxin in humans (1974) (0)
Vibriocidal antibody titer rise after rectal or anal administration of Vibrio cholerae in dogs. (1978) (0)
HOUR OF ONSET OF CHOLERA AND DIARRHŒA (1979) (0)
Measles vaccine (1969) (0)
RICE POWDER AND ELECTROLYTE SOLUTIONS (1982) (0)
Sucrose or glucose for diarrhoea. (1977) (0)
Bacterial resistance to norfloxacin and other newer quinolones: pattern and prospects. (1988) (0)
Oral rehydration solution. (1982) (0)
Biohydrogenation of cholesterol as an index of bacterial 7 alpha-dehydroxylase activity. (1981) (0)
Hepatitis A vaccine. (1996) (0)
ImmmgedityoftwovwtltreeinjectionsofinaW~tisA vaccine in adults (1996) (0)
Non-Vibrio Cholera: A Current Overview (1975) (0)
Single-Dose Vaccines. (2015) (0)
Solutions for oral rehydration. (1987) (0)
Oral Rehydration for Cholera. Authors' reply (2009) (0)
Correspondence (1985) (0)
Voluminous diarrhea associated with infantis infection in two siblings. (1974) (0)
Eliminating Cholera Incidence and Mortality: Unfulfilled Tasks (2022) (0)

This paper list is powered by the following services:

Other Resources About David Nalin

en.wikipedia.org

What Schools Are Affiliated With David Nalin?

David Nalin is affiliated with the following schools: